During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials?
In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN trial (NCT02874742) and the CASSIOPEIA trial (NCT02541383).
Podden och tillhörande omslagsbild på den här sidan tillhör Scientific Education Support. Innehållet i podden är skapat av Scientific Education Support och inte av, eller tillsammans med, Poddtoppen.
